EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The emerging concern of IMP variants being resistant to the only IMP-type metallo-β-lactamase inhibitor, xeruborbactam

Christophe Le Terrier iD, Salvador I Drusin, Patrice Nordmann iD, Johann Pitout, Gisele Peirano, Alejandro J Vila iD, Diego M Moreno iD, Laurent Poirel iD

Antimicrobial Agents and Chemotherapy · 09.06.2025

DOI: 10.1128/aac.00297-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, online erschienen am 09.06.2025. Verfasst von Christophe Le Terrier und 7 weiteren Autor:innen. Beteiligte Einrichtung: Medical and Molecular Microbiology, Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland. Hauptthemen laut MEDLINE: beta-Lactamases, beta-Lactamase Inhibitors, Anti-Bacterial Agents, Monobactams. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metallo-β-lactamases (MBLs) of IMP type are not inhibited by currently commercialized β-lactamase inhibitors, including taniborbactam (TAN), which inhibits only NDM- and VIM-type enzymes. However, the development of xeruborbactam (XER), which additionally inhibits IMP enzymes, may provide effective drug combinations such as meropenem-XER (MEM-XER) against most MBL producers. Thirty-two IMP-producing clinical gram-negative isolates were tested for MEM-XER. Susceptibility testing of β-lactams with TAN or XER at 4 or 8 µg/mL was performed. Noticeably, MEM-XER remained ineffective against all IMP-producing Pseudomonas aeruginosa isolates. By contrast, supplementation with XER significantly lowered MEM MICs for several IMP-producing Enterobacterales isolates, except for isolates and recombinant E. coli strains producing IMP-6, IMP-10, IMP-14, and IMP-26. Interestingly, IMP-59 producers showed susceptibility to both TAN- and XER-based combinations, although IMP enzymes are not supposed to be inhibited by TAN. Determinations of 50% inhibitory concentration (IC 50 ) values of XER showed values being >15-fold higher for IMP-6, IMP-10, IMP-14, and IMP-26 compared with IMP-1. Interestingly, the IC 50 value of TAN for IMP-59 was found in the same range as that for NDM-1 (7 µM). Finally, structural analyses and molecular modeling simulations indicated that the Ser262Gly mutation in IMP-6 may alter the electronic properties of the active site, whereas the Phe residue in IMP-10 may exert a steric effect counteracting XER binding. Resistance to XER in IMP-6, IMP-10, IMP-14, and IMP-26 variants, conferring resistance to MEM-XER, might be considered a serious concern since MEM-XER will be supposed to be a salvage therapy for MBL-, and especially IMP-producing Enterobacterales infections.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

beta-Lactamasesbeta-Lactamase InhibitorsAnti-Bacterial AgentsMonobactamsMicrobial Sensitivity TestsPseudomonas aeruginosaMeropenemEscherichia coliMolecular Docking Simulationbeta-LactamsBorinic AcidsCarboxylic Acids

Stichwörter der Autor:innen

IMPcarbapenemasemetallo-beta-lactamasexeruborbactam

Substanzen

beta-Lactamasesbeta-Lactamase InhibitorsAnti-Bacterial AgentsMeropenemtaniborbactamMonobactamsbeta-LactamsBorinic AcidsCarboxylic Acids

Autor:innen und Institutionen

  • Medical and Molecular Microbiology, Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland.
  • Division of Intensive Care, Department of Acute Care Medicine, Geneva University Hospitals, Geneva, Switzerland.
  • Department of Anaesthesiology, Pharmacology, Intensive Care and Emergency Medicine, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
  • Facultad de Ciencias Bioquímicas y Farmacéuticas, Universidad Nacional de Rosario, Rosario, Santa Fe, Argentina.
  • Instituto de Química Rosario (IQUIR, CONICET-UNR), Rosario, Santa Fe, Argentina.
  • Swiss National Reference Center for Emerging Antibiotic Resistance, Fribourg, Switzerland.

ORCID-Profile: Christophe Le Terrier, Patrice Nordmann, Alejandro J Vila, Diego M Moreno, Laurent Poirel

Förderung

  • NIAID NIH HHS

Zitieren

APA

Le Terrier, C., Drusin, S. I., Nordmann, P., Pitout, J., Peirano, G., Vila, A. J., Moreno, D. M., & Poirel, L. (2025). The emerging concern of IMP variants being resistant to the only IMP-type metallo-β-lactamase inhibitor, xeruborbactam. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00297-25

Vancouver

Le Terrier C, Drusin SI, Nordmann P, Pitout J, Peirano G, Vila AJ, et al. The emerging concern of IMP variants being resistant to the only IMP-type metallo-β-lactamase inhibitor, xeruborbactam. Antimicrobial Agents and Chemotherapy. 2025. doi:10.1128/aac.00297-25

BibTeX
@article{LeTerrier2025,
  author = {Le Terrier, Christophe and Drusin, Salvador I and Nordmann, Patrice and Pitout, Johann and Peirano, Gisele and Vila, Alejandro J and Moreno, Diego M and Poirel, Laurent},
  title = {The emerging concern of IMP variants being resistant to the only IMP-type metallo-β-lactamase inhibitor, xeruborbactam},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2025},
  doi = {10.1128/aac.00297-25}
}
Kostenlos starten →